Institutional Ownership
Achilles Therapeutics Pl-Adr
CUSIP 00449L102COM698Q1 2026
13D / 13G Filings
20
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
27.3%
Max % of class reported
Institutional Holders
3
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
20 filings · latest Feb 13, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 13, 2025 | Bml Investment Partners, L.P. | 13G/A | 10.0% | 4.10M | SEC |
| 2 | Nov 14, 2024 | Baker Bros. Advisors LP | 13G/A | — | — | SEC |
| 3 | Sep 25, 2024 | Bml Investment Partners, L.P. | 13G | 10.0% | 4.10M | SEC |
| 4 | Mar 29, 2024 | Artal International S.C.A. | 13G/A | 1.9% | 755.4K | SEC |
| 5 | Feb 14, 2024 | Baker Bros. Advisors LP | 13G/A | 8.1% | 3.31M | SEC |
| 6 | Feb 13, 2024 | Syncona Portfolio Ltd | 13G/A | 27.2% | 11.09M | SEC |
| 7 | Feb 14, 2023 | Redmile Group, LLC | 13G/A | 3.9% | 1.61M | SEC |
| 8 | Feb 14, 2023 | Baker Bros. Advisors LP | 13G/A | 9.9% | 4.21M | SEC |
| 9 | Feb 14, 2023 | Point72 Asset Management, L.P. | 13G/A | 3.6% | 1.41M | SEC |
| 10 | Feb 13, 2023 | Artal International S.C.A. | 13G/A | 5.5% | 2.26M | SEC |
10 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Achilles Therapeutics Pl-Adr.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Trium Capital LLP | 30.8K | $45.5K |
| 2 | Rhumbline Advisers | 4.5K | $6.6K |
| 3 | Gamma Investing LLC | 806 | $1.2K |